TGFB1 and neoplasm: Recent renewed interest was spurred by clinical success of immunotherapies, particularly immune checkpoint blockade (ICB) agents (see the sidebar titled Immune Checkpoint Blockade), when placed in context with the potent immunosuppressive effects of TGFβ signaling in normal and tumor tissues (Arteaga et al. 1993, Gorelik & Flavell 2001, Thomas & Massague 2005, Flavell et al. 2010).